it
Carrello
Pramiracetam (CAS 68497-62-1) is supplied by Rexar as a research-grade chemical reference material for analytical chemistry, structural verification and laboratory comparison workflows. This synthetic racetam derivative is provided exclusively for controlled research environments requiring confirmed chemical identity, reproducible analytical characteristics and consistent documentation standards.
Pramiracetam is available directly through the Rexar webshop and is supplied in sealed laboratory packaging for distribution within the European Union.
Rexar Technical Compound Datasheet (PDF)
Pramiracetam is a substituted 2-oxo-pyrrolidinone derivative belonging to the racetam class of synthetic small molecules. The compound consists of a pyrrolidone core linked through an acetamide bridge to a diisopropylaminoethyl side chain. This structural configuration introduces both amide and tertiary amine functionalities within a compact molecular framework.
The molecular formula C14H27N3O2 and molecular weight of 269.38 g/mol reflect a relatively high nitrogen content compared to other racetam analogues. The tertiary amine moiety contributes to defined polarity and basicity characteristics, which may influence chromatographic retention behaviour and spectroscopic profile under controlled analytical conditions.
The defining structural element of Pramiracetam is the 2-oxopyrrolidin-1-yl acetamide scaffold. The lactam ring (pyrrolidin-2-one) exhibits classical amide resonance stabilisation, resulting in partial double-bond character across the C–N bond and restricted rotational freedom.
This constrained geometry supports reproducible NMR and IR characteristics, which are critical in structural verification workflows. Within racetam-type derivatives, substitution patterns around the nitrogen atom and side chain architecture differentiate individual compounds in terms of polarity, steric profile and chromatographic behaviour.
The di(propan-2-yl)amino group introduces a tertiary amine centre that increases overall lipophilicity relative to simpler racetam analogues. This tertiary amine may be protonated under acidic conditions, altering chromatographic mobility and retention behaviour depending on mobile phase pH.
From an analytical chemistry perspective, protonation state considerations are relevant in method development and gradient optimisation, particularly in reversed-phase liquid chromatography systems.
The presence of multiple nitrogen atoms provides distinct spectroscopic signatures. Carbonyl stretching bands corresponding to amide groups are typically observable in IR spectra, while tertiary amine environments contribute characteristic signals in NMR analysis.
Pramiracetam’s molecular conformation is influenced by restricted amide rotation and steric bulk introduced by the diisopropyl substituents. The tertiary amine side chain may adopt multiple conformations depending on solvent environment and temperature.
Computational conformational modelling may evaluate torsional angles across the ethyl bridge and amide linkage, assisting in the interpretation of subtle spectral variations observed under different experimental conditions.
The combination of polar amide groups and hydrophobic isopropyl substituents results in amphiphilic characteristics. This balanced polarity may influence dissolution behaviour and chromatographic separation properties.
Key analytical parameters that may be evaluated include:
Mass spectrometric analysis confirms the molecular ion corresponding to 269.38 g/mol. Fragmentation patterns may involve cleavage at the amide bond or tertiary amine side chain, generating diagnostic fragment ions useful in structural confirmation workflows.
The presence of multiple nitrogen atoms may influence ionisation efficiency under electrospray or atmospheric pressure chemical ionisation conditions.
In reversed-phase chromatographic systems, Pramiracetam’s retention behaviour may be influenced by mobile phase composition, buffer pH and organic modifier percentage. Protonation of the tertiary amine can alter polarity and retention characteristics.
Method development may include optimisation of gradient slope, buffer concentration and column selection to achieve reproducible peak shape and resolution when analysed alongside structurally related compounds.
Pramiracetam is typically encountered as a white crystalline powder. Solid-state interactions may involve hydrogen bonding between amide functionalities and intermolecular van der Waals forces contributing to crystal lattice stability.
Controlled storage conditions assist in maintaining consistent physical appearance and analytical performance over time.
Pramiracetam | CAS: 68497-62-1 | Molecular formula: C14H27N3O2 | Molecular weight: 269.38 g/mol.
Pramiracetam may serve as a qualitative reference material in analytical laboratories performing compound verification, retention time comparison and spectroscopic confirmation. It may be incorporated into method validation procedures or comparative profiling workflows involving racetam derivatives.
What is the CAS number of Pramiracetam?
The CAS number of Pramiracetam is 68497-62-1.
In which form is Pramiracetam supplied?
This product is supplied as a white crystalline powder in sealed laboratory packaging.
Is this product intended for human or animal use?
No. This material is supplied exclusively as a laboratory reference compound.
Is Pramiracetam available for shipment within the EU?
Yes. Orders are supplied through the Rexar webshop in sealed laboratory packaging.
Pramiracetam exhibits a distinct electronic distribution due to the combined presence of two amide functionalities and a tertiary amine centre. The amide carbonyl groups contribute strong dipole moments, while the tertiary amine provides an electron-rich nitrogen atom capable of protonation under controlled acidic conditions.
Electron density mapping models indicate that the carbonyl oxygens act as primary hydrogen bond acceptor sites, while the tertiary amine nitrogen may participate in protonation equilibria depending on environmental pH. These features influence ionisation behaviour and analytical detectability in LC-MS workflows.
The tertiary amine present in Pramiracetam introduces defined basicity characteristics. Under acidic chromatographic conditions, partial protonation may occur, resulting in altered polarity and retention behaviour. In neutral or mildly basic systems, the molecule may remain predominantly in its non-protonated state.
Understanding the ionisation profile is important in reversed-phase chromatography, particularly when evaluating peak symmetry, tailing behaviour and resolution relative to other tertiary amine-containing derivatives.
The diisopropyl substituents contribute hydrophobic surface area, while the amide groups introduce polar functionality. This amphiphilic balance influences solubility behaviour and stationary phase interactions in chromatographic systems.
Compared to smaller racetam analogues, the increased alkyl substitution may result in moderately increased retention under identical gradient conditions. Such comparative retention modelling is relevant when establishing multi-analyte methods involving structurally related compounds.
In the solid state, intermolecular hydrogen bonding between amide carbonyl groups and adjacent hydrogen donors may contribute to lattice stability. Van der Waals interactions between isopropyl groups can further stabilise crystalline packing.
Consistent crystal morphology supports reproducible dissolution behaviour and analytical sample preparation when stored under recommended conditions.
Under standard laboratory storage conditions (8–20 °C, dry environment), amide-containing compounds such as Pramiracetam are generally stable. Elevated temperatures or extreme pH conditions may theoretically influence hydrolysis rates; however, such conditions fall outside recommended storage parameters.
Thermal analysis techniques such as differential scanning calorimetry (DSC) may be employed in research settings to characterise melting transitions and assess solid-state consistency.
Within the racetam class, substitution at the nitrogen position significantly influences physicochemical behaviour. Pramiracetam’s extended diisopropylaminoethyl side chain distinguishes it from smaller derivatives by increasing steric bulk and altering hydrophobic surface area.
In comparative profiling studies, structural differences may manifest as variations in chromatographic retention time, solubility characteristics and spectroscopic fine structure. Such differences are useful for analytical differentiation when multiple racetam analogues are evaluated in parallel.
Proton NMR analysis typically reveals distinct signals corresponding to the isopropyl methyl groups, methine protons and methylene linkages. The lactam and acetamide carbonyl carbons generate identifiable signals in 13C NMR spectra.
Coupling patterns and integration ratios assist in confirming structural integrity and distinguishing Pramiracetam from closely related pyrrolidone derivatives.
Infrared spectroscopy commonly demonstrates strong amide carbonyl stretching bands alongside N–H bending vibrations. The tertiary amine does not exhibit N–H stretching, which differentiates it from secondary amine-containing structures.
Vibrational modes associated with aliphatic C–H stretching and amide bending further contribute to a reproducible IR fingerprint useful in identity verification workflows.
Under electrospray ionisation conditions, protonated molecular ions may be observed. Fragmentation may occur at the amide linkage or along the tertiary amine side chain, producing diagnostic fragment ions consistent with the proposed structure.
These fragmentation pathways support compound confirmation when used in combination with retention time and high-resolution mass analysis.
As a research-grade reference material, Pramiracetam is supplied in sealed laboratory packaging to preserve purity and minimise environmental exposure. Controlled storage conditions reduce moisture uptake and maintain consistent analytical characteristics.
Batch identification labelling supports traceability and documentation within laboratory record systems, ensuring reproducibility in comparative analytical studies.
This product is intended for laboratory research use only. It is not intended for human or animal consumption, nor for medical, diagnostic, or therapeutic applications. This compound is not intended to diagnose, treat, cure, or prevent any disease.
| Intended use: | Laboratory research and analytical reference purposes only |
| Application area: | Analytical chemistry, reference comparison and method development |
| End user: | Professional users in controlled research environments |
| Regulatory classification: | Chemical reference material |
